Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of Trem-1 in UV-induced Immune Suppression
NCT05020496Phase 1Active, not recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Mar 2022
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of diphencyprone (3 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Contact hypersensitivity. Started Mar 2022; status: active, not recruiting.
02
Drugs
diphencyprone
Beyond the preview
Go deeper on NCT05020496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020496.